---
title: "Evommune licenses preclinical VAV1 degrader and raises $30 million after two Phase 2b failures"
url: "https://aibio.space/news/evommune-licenses-preclinical-vav1-degrader-raises-30-million-after/"
event_date: "2026-11-04"
date_published: "2026-11-05"
description: "Evommune will pay Hinova $20 million in cash plus pre-funded warrants for 1,262,413 shares, and sold 4,966,889 shares at $6.04 through Morgan Stanley and Leerink. EVO756 missed its endpoints in hives and eczema this year."
---

# Evommune licenses preclinical VAV1 degrader and raises $30 million after two Phase 2b failures

Evommune, Inc. (NYSE: EVMN) agreed on November 4, 2026 to in-license EVO570 from Hinova Pharmaceuticals Inc. (SSE: 688302). EVO570 is an oral VAV1 molecular glue degrader that has not yet been tested in people. On the same day Evommune sold $30 million of new stock. President and Chief Executive Officer Luis Peña signed the filing. The deal comes after two failures for the company's lead clinical drug this year. EVO756 missed its primary endpoint in chronic spontaneous urticaria in June, then missed its primary and secondary endpoints in atopic dermatitis in September, and Evommune stopped development in both. Shareholders are paying for the restart through dilution twice: pre-funded warrants to Hinova and a private placement. [Form 8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm)

## What Evommune pays Hinova

Evommune gets exclusive rights to Hinova's VAV1 degraders, including EVO570 (formerly HC118), for all human and animal uses outside mainland China, Hong Kong, Macau and Taiwan. Hinova keeps Greater China. The upfront is $20.0 million in cash plus pre-funded warrants for up to 1,262,413 shares, issued to a wholly owned Hinova subsidiary. Those warrants are valued at $10.0 million on a 45-day average closing price and carry a $0.001 exercise price. They run until November 4, 2036. [Form 8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm)

The stock part may not stay stock. A 4.99% ownership limit applies, and Evommune can settle any excess in cash or waive the limit. Hinova can also ask for cash in place of shares at 90% of the 45-day average price. Hinova is eligible for up to $150.0 million in development and regulatory milestones and up to $920.0 million in commercial milestones. That is the "approximately $1.1 billion" in the release. Royalties run from the mid single digits to the low double digits. The license agreement itself will only be filed with the 10-K for 2026. [Form 8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm)

## The private placement and the banks

Evommune agreed to sell 4,966,889 shares at $6.04 each, for gross proceeds of about $30.0 million. The deal was expected to close on or about November 6. Buyers include Adage Capital Partners, L.P., Balyasny Asset Management, Defilade Capital Management, OrbiMed and Squadron Capital Management. Morgan Stanley & Co. LLC and Leerink Partners LLC were placement agents, and Oppenheimer & Co. Inc. was capital markets advisor. The company will pay "customary" placement fees but gives no amount. It must file a resale registration statement on Form S-3 within 60 days of closing. [Private placement release](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-ex99_2.htm)

BFC Group was exclusive financial advisor and Fangda Partners exclusive legal advisor to Hinova. The filings name no legal counsel for Evommune or for the placement agents. [License release](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-ex99_1.htm)

## What the science shows so far

Everything offered is preclinical. The release says EVO570 showed "promising activity" in animal models and "greater potency in human immune cells than competitor VAV1 degraders." It names no competitor, gives no potency figures and does not say how many models were used. The comparison also tells readers that other VAV1 degraders exist. Chief Scientific Officer Dr. Jeegar Patel said VAV1 offers "a potential path to JAK-like efficacy" without the safety problems of other therapies. That is a hypothesis about the target, not a finding in patients. The case rests on VAV1 being largely restricted to immune cells. [License release](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-ex99_1.htm)

The IND has been accepted in the United States and submitted in China. A Phase 1 trial of safety, pharmacokinetics and target engagement is "on track to begin imminently," and Evommune plans a Phase 2 trial in rheumatoid arthritis in 2027. Greg Moss, Chief Business and Legal Officer, said the deal keeps "a disciplined portfolio management approach." Hinova Founder and Chairman Dr. Yuanwei Chen called Evommune "the ideal collaborator."

## The money behind it

Evommune lost $53.9 million in the first half of 2026, and operations used $47.8 million in cash. [Form 10-Q](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm) After the atopic dermatitis failure, the company said its cash would last into 2029. It is still testing EVO756 in migraine prophylaxis. [Form 8-K, September 8](https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm) It now estimates that the placement plus cash, cash equivalents and investments at September 30, 2026 come to about $292.3 million, enough into the second half of 2029. That figure is preliminary and unaudited, and the company warns that differences could be material. [Form 8-K](https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm)

The migraine Phase 2b of EVO756 began in July 2026, with initial results expected in 2027. [Form 10-Q](https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm) The next filings to read are the third-quarter 10-Q, which will replace the estimate with reported numbers, and the S-3 for the placement shares.

Sources

- https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-ex99_1.htm
- https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm
- https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-ex99_2.htm
- https://www.sec.gov/Archives/edgar/data/2044725/000119312526337984/evmn-20260630.htm
- https://www.sec.gov/Archives/edgar/data/2044725/000119312526385430/evmn-20260908.htm
